{
  "id": "601d74681cb411341a000042",
  "type": "factoid",
  "question": "Which mutation is targeted by Sotorasib?",
  "ideal_answer": "Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
    "http://www.ncbi.nlm.nih.gov/pubmed/33097477",
    "http://www.ncbi.nlm.nih.gov/pubmed/33004338"
  ],
  "snippets": [
    {
      "text": "In a phase I trial, the KRASG12C inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33097477",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In a phase I trial, the KRASG12C inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33004338",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grad",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "THODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "er cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "KRASG12C"
}